Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Medarex and Bristol-Myers Squibb report mixed melanoma data
The results from study 008, conducted under special protocol assessment (SPA), did not meet the primary endpoint, which was to rule out a best objective response rate of
The results from study 008, conducted under special protocol assessment (SPA), did not meet the primary endpoint, which was to rule out a best objective response rate of
The company said that BL-5010 is a convenient treatment that offers an alternative to painful, invasive and expensive removal treatments such as surgery, cryotherapy or laser treatment. Because
The doses tested in the study were high, medium, low and zero. All dosages were administered according to a previously developed optimum schedule, which included an induction dose
The initial analysis of the first 46 patients of a 200 patient Phase-II, multi-center open-label clinical study, NHL-003, showed encouraging results that are consistent with those of the
A 53% response rate was demonstrated at the 90mg dose with a median time to response of less than two months. The overall results indicate a 36% response
The Good Health Company’s programs are designed to empower individuals to take control of their health and are said to be highly complementary to the Focused Health Solutions
Under terms of the agreement, Volcano will pay $25 million in cash at closing, which is expected to occur by the end of the year. In addition, Volcano
Under the agreement, ChemDiv will be initiating a high-throughput screen for small molecule inhibitors of tyrosylprotein sulfotransferases. The collaboration provides Siwa Biotech with access to ChemDiv’s expertise in
The data presented showed that seven out of ten patients achieved responses including three complete remissions (30%), four partial remissions (40%), one patient with stable disease, and two
The Nexfin monitors are said to provide provide precise and easy to use continuous non-invasive blood pressure and cardiac output monitoring. Bmeye received CE market approval earlier this